Decision curve analysis (DCA) and calibration curve show that the T1WIintra+peri + CE-T1WIintra+peri model was a reliable clinical treatment tool for predicting MGMT promoter methylation status in glioblastoma patients (Figs. 6 and 7). This evidence concerns the gene MGMT and glioblastoma.